Agile Therapeutics Inc. (AGRX)
NASDAQ: AGRX
· Real-Time Price · USD
1.51
0.05 (3.42%)
At close: Aug 22, 2024, 9:58 PM
Agile Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 21.57M | 21.5M | 19.59M | 19.97M | 16.31M | 12.94M | 10.88M | 8.4M | 6.69M | 5.75M | 4.1M | 3.34M | 2.05M | 865K |
Cost of Revenue | 7.84M | 8.65M | 8.98M | 8.44M | 7.39M | 7.31M | 6.84M | 10.88M | 12.17M | 11.09M | 10.72M | 5.3M | 2.59M | 1.44M |
Gross Profit | 13.72M | 12.84M | 10.61M | 11.53M | 8.93M | 5.63M | 4.05M | -2.48M | -5.48M | -5.34M | -6.62M | -1.96M | -538K | -578K |
Operating Income | -13.55M | -15.94M | -19.89M | -22.71M | -26.3M | -32.57M | -41.43M | -56.92M | -65.11M | -70.36M | -71.01M | -65.39M | -64.27M | -57.66M |
Interest Income | 81K | 68K | 78K | 91K | 124K | 111K | 79K | 50K | 5K | 10K | 25K | 49K | 85K | 193K |
Pretax Income | -15.86M | -7.79M | -14.47M | -13.93M | -32.79M | -41.2M | -52.26M | -71.69M | -68.79M | -74.21M | -74.89M | -69.16M | -67.91M | -61.1M |
Net Income | -15.86M | -7.79M | -12.69M | -21.5M | -42.75M | -51.16M | -59.32M | -69.39M | -64.12M | -69.54M | -74.89M | -69.16M | -67.91M | -61.1M |
Selling & General & Admin | 25.49M | 26.82M | 28.27M | 31.72M | 32.62M | 35.43M | 42.23M | 49.88M | 54.26M | 59.65M | 58.17M | 55.85M | 54.08M | 44.63M |
Research & Development | 1.79M | 1.96M | 2.23M | 2.52M | 2.61M | 2.76M | 3.25M | 4.56M | 5.36M | 5.37M | 6.22M | 7.58M | 9.65M | 12.45M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 27.28M | 28.77M | 30.5M | 34.24M | 35.22M | 38.19M | 45.48M | 54.44M | 59.62M | 65.02M | 64.39M | 63.43M | 63.73M | 57.08M |
Interest Expense | 831K | 1.2M | 1.42M | 1.55M | 2.21M | 2.66M | 3.13M | 3.7M | 3.69M | 3.86M | 3.91M | 3.82M | 3.72M | 3.63M |
Selling & Marketing Expenses | 15.99M | 16.78M | 17.77M | 20.88M | 21.64M | 24.48M | 30.37M | 36.19M | 40.02M | 44.32M | 42.93M | 40.93M | 31.55M | 19.83M |
Cost & Expenses | 35.12M | 37.43M | 39.48M | 42.68M | 42.61M | 45.51M | 52.32M | 65.32M | 71.79M | 76.11M | 75.11M | 68.72M | 66.32M | 58.52M |
Income Tax Expense | n/a | n/a | -1.78M | 7.57M | 9.95M | 17.01M | 14.11M | 5.76M | 3.38M | -3.67M | 1.02M | -80K | -44K | -51K |
Shares Outstanding (Basic) | 6.86M | 4.63M | 2.96M | 2.95M | 1.77M | 912.04K | 824.65K | 739.96K | 90.2K | 62.3K | 58.36K | 46.59K | 44.35K | 43.81K |
Shares Outstanding (Diluted) | 6.86M | 4.63M | 2.96M | 2.95M | 1.77M | 912.04K | 824.65K | 739.96K | 90.2K | 62.3K | 58.96K | 46.88K | 44.35K | 43.81K |
EPS (Basic) | -3.23 | -3.65 | -7.89 | -22.48 | -52.01 | -185.32 | -370.26 | -754.38 | -1.08K | -1.35K | -1.55K | -1.55K | -1.55K | -1.4K |
EPS (Diluted) | -3.23 | -3.65 | -7.89 | -22.48 | -52.01 | -185.32 | -370.26 | -750.34 | -1.08K | -1.34K | -1.54K | -1.55K | -1.55K | -1.4K |
EBITDA | -9.67M | -10.27M | -12.53M | -15.44M | -22.41M | -22.82M | -31.52M | -46.46M | -54.36M | -66.7M | -68.76M | -63.69M | -63.09M | -56.87M |
EBIT | -15.03M | -6.59M | -13.05M | 9.79M | 5.32M | 4.41M | -4.79M | -45.82M | -56.66M | -68.96M | -70.98M | -65.34M | -64.19M | -57.47M |
Depreciation & Amortization | 301K | 396K | 386K | 377K | 541K | 1.04M | 1.53M | 2.02M | 2.31M | 2.27M | 2.22M | 1.78M | 1.28M | 778K |